HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer
- Fengxia Chen
- Zhicai Zhang
- Yihan Yu
- Qiuyu Liu
- Feifei Pu
Affiliations: Department of Medical Oncology, General Hospital of The Yangtze River Shipping, Wuhan Polytechnic University, Wuhan, Hubei 430010, P.R. China, Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Pediatrics, The Third Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China, Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, Henan 450003, P.R. China
- Published online on: May 4, 2020 https://doi.org/10.3892/ijo.2020.5057
Copyright: © Chen
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Human sulfatase‑1 (HSulf‑1) is emerging as a novel prognostic biomarker in breast cancer. Previous studies demonstrated HSulf‑1 to function as a negative regulator of cyclin D1 in breast cancer. Accumulating preclinical evidence is supporting the efficacy of cyclin‑dependent kinase (CDK) 4/6 inhibitors against the luminal androgen receptor sub‑type of triple‑negative breast cancer (TNBC). It was therefore hypothesized that HSulf‑1 may cooperate with CDK4/6 inhibitors to control cell cycle progression in breast cancer cells. HSulf‑1 expression was found to be downregulated in TNBC tissues and cell lines compared with that in healthy tissues and non‑breast cancer cell lines, respectively. High levels of HSulf‑1 expression was also found to be associated with increased progression‑free survival and overall survival in patients with TNBC. Functionally, it was demonstrated that HSulf‑1 served as tumor suppressor in TNBC by inducing cell cycle arrest and apoptosis whilst inhibiting proliferation, epithelial‑mesenchymal transition, migration and invasion. Subsequent overexpression of HSulf‑1 coupled with treatment with the CDK4/6 inhibitor palbociclib exhibited a synergistic antitumor effect on retinoblastoma (RB)‑positive TNBC. Further studies revealed the mechanism underlying this cooperative antiproliferative effect involved to be due to the prohibitive effects of HSulf‑1 on the palbociclib‑induced accumulation of cyclin D1 through AKT/STAT3 and ERK1/2/STAT3 signaling. Taken together, findings from the present study not only suggest that HSulf‑1 may be a potential therapeutic target for TNBC, but also indicate that combinatorial treatment could be an alternative therapeutic option for RB‑positive TNBC, which may open novel perspectives.